Retrospective review of metastatic castration resistant prostate cancer (mCRPC) patients treated with sequential novel hormone therapies, abiraterone and enzalutamide (NHT1-NHT2) verses patient who received intercalated docetaxel between novel hormone therapies (NHT1-D-NHT2)

Trial Profile

Retrospective review of metastatic castration resistant prostate cancer (mCRPC) patients treated with sequential novel hormone therapies, abiraterone and enzalutamide (NHT1-NHT2) verses patient who received intercalated docetaxel between novel hormone therapies (NHT1-D-NHT2)

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Aug 2016

At a glance

  • Drugs Abiraterone (Primary) ; Docetaxel (Primary) ; Enzalutamide (Primary)
  • Indications Prostate cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 17 Aug 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top